ARTICLE | Clinical News

EC approves Celltrion's Herceptin biosimilar

February 16, 2018 7:58 PM UTC

Celltrion Inc. (KOSDAQ:068270) said the European Commission approved Herzuma, a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit. The biosimilar is indicated to treat HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer -- the same approved indications as Herceptin...